A new model of
addiction care with psychedelic therapeutics
Journey's mission is to unlock the promising science behind psychedelics to provide durable remission to patients suffering from addiction
Backed by world class investors
We believe a powerful new model of addiction treatment can be created by combining the promise of psychedelic therapies with an integrated care model that includes psychotherapy and community support.
- Enable real-world research on psychedelic therapeutics and high-quality, integrated care through our network of Centers of Excellence, created in collaboration with select addiction treatment centers across the U.S.
- Advance psychedelic therapeutic development, including Journey’s own drug program, JOUR-5700, Mescaline HCl for Alcohol Use Disorder
Journey Colab is focused on finding new and better solutions for those who are in desperate need of durable remission from this chronic, relapsing condition.
Americans suffer from addiction today. Only 10% receive lasting benefit from current treatments. ~75% of substance use cases are alcohol-related.
in estimated annual expenditure in U.S. on SUD (2020)
of adults with SUD don’t get treatment
in the estimated economic burden in the U.S. from SUD (2022)
Built with reciprocity in mind
Through our unique stakeholder structure, we have built an experienced team dedicated to our mission of creating scientifically rigorous and clinically validated treatments and improving equitable access to care. Ten percent of our founding equity is dedicated to sharing success with community stakeholders, including Indigenous communities, to increase equitable access to care and recruit employees and partnerships.